A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma

Levi S Downs, Patricia L. Judson, Peter A Argenta, Rahel G Ghebre, Melissa A Geller, Robin L. Bliss, Matthew P. Boente, William A. Nahhas, Samir Z. Abu-Ghazaleh, M. Dwight Chen, Linda F Carson

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

BACKGROUND. Thalidomide is an antiangiogenic agent with immune modulating potential. The objective of this study was to determine response rates among women who were treated for recurrent ovarian cancer using topotecan with or without thalidomide. METHODS. Women were enrolled in this multicenter, prospective, randomized phase 2 trial between April 2001 and July 2005. Eligible patients had recurrent epithelial ovarian carcinoma with measurable disease or elevated CA 125 values. Patients had received prior platinum-based chemotherapy. Treatment arms received topotecan at a dose of 1.25 mg/m2 on Days 1 through 5 of a 21-day cycle with or without thalidomide starting at a dose of 200 mg per day and then increasing the dose as tolerated. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria. The chi-square test was used to assess differences in response and toxicity, and the log-rank test was used to compare Kaplan-Meier survival curves. RESULTS. The analysis included 69 women (39 women in the control arm and 30 women in the thalidomide arm). Known prognostic factors, including platinum sensitivity, were represented equally in each arm. The median thalidomide dose was 200 mg per day. The overall response rate in the control arm was 21% (complete response [CR] rate, 18%; partial response [PR] rate, 3%) compared with 47% in the thalidomide arm (CR rate, 30%; PR rate, 17%) (P = .03). The median progression-free survival for the control arm was 4 months compared with 6 months in the thalidomide arm (P = .02). The median overall survival was 15 months in the control arm and 19 months in the thalidomide arm (P = .67). Toxicities were similar between groups. CONCLUSIONS. The addition of thalidomide to topotecan for the treatment of recurrent ovarian cancer appears to improve response rates, and the authors believe that it warrants study through larger phase 3 trials.

Original languageEnglish (US)
Pages (from-to)331-339
Number of pages9
JournalCancer
Volume112
Issue number2
DOIs
StatePublished - Jan 15 2008

Fingerprint

Topotecan
Thalidomide
Carcinoma
Platinum
Ovarian Neoplasms
Angiogenesis Inhibitors
National Cancer Institute (U.S.)
Kaplan-Meier Estimate
Chi-Square Distribution
Disease-Free Survival
Drug Therapy

Keywords

  • Angiogenesis inhibitor
  • Phase 2 trial
  • Platinum sensitivity
  • Recurrent ovarian cancer
  • System for Thalidomide Education and Prescribing Safety

Cite this

A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. / Downs, Levi S; Judson, Patricia L.; Argenta, Peter A; Ghebre, Rahel G; Geller, Melissa A; Bliss, Robin L.; Boente, Matthew P.; Nahhas, William A.; Abu-Ghazaleh, Samir Z.; Chen, M. Dwight; Carson, Linda F.

In: Cancer, Vol. 112, No. 2, 15.01.2008, p. 331-339.

Research output: Contribution to journalArticle

Downs, Levi S ; Judson, Patricia L. ; Argenta, Peter A ; Ghebre, Rahel G ; Geller, Melissa A ; Bliss, Robin L. ; Boente, Matthew P. ; Nahhas, William A. ; Abu-Ghazaleh, Samir Z. ; Chen, M. Dwight ; Carson, Linda F. / A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. In: Cancer. 2008 ; Vol. 112, No. 2. pp. 331-339.
@article{ec902160b5af44e0a3456f90d0b4e352,
title = "A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma",
abstract = "BACKGROUND. Thalidomide is an antiangiogenic agent with immune modulating potential. The objective of this study was to determine response rates among women who were treated for recurrent ovarian cancer using topotecan with or without thalidomide. METHODS. Women were enrolled in this multicenter, prospective, randomized phase 2 trial between April 2001 and July 2005. Eligible patients had recurrent epithelial ovarian carcinoma with measurable disease or elevated CA 125 values. Patients had received prior platinum-based chemotherapy. Treatment arms received topotecan at a dose of 1.25 mg/m2 on Days 1 through 5 of a 21-day cycle with or without thalidomide starting at a dose of 200 mg per day and then increasing the dose as tolerated. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria. The chi-square test was used to assess differences in response and toxicity, and the log-rank test was used to compare Kaplan-Meier survival curves. RESULTS. The analysis included 69 women (39 women in the control arm and 30 women in the thalidomide arm). Known prognostic factors, including platinum sensitivity, were represented equally in each arm. The median thalidomide dose was 200 mg per day. The overall response rate in the control arm was 21{\%} (complete response [CR] rate, 18{\%}; partial response [PR] rate, 3{\%}) compared with 47{\%} in the thalidomide arm (CR rate, 30{\%}; PR rate, 17{\%}) (P = .03). The median progression-free survival for the control arm was 4 months compared with 6 months in the thalidomide arm (P = .02). The median overall survival was 15 months in the control arm and 19 months in the thalidomide arm (P = .67). Toxicities were similar between groups. CONCLUSIONS. The addition of thalidomide to topotecan for the treatment of recurrent ovarian cancer appears to improve response rates, and the authors believe that it warrants study through larger phase 3 trials.",
keywords = "Angiogenesis inhibitor, Phase 2 trial, Platinum sensitivity, Recurrent ovarian cancer, System for Thalidomide Education and Prescribing Safety",
author = "Downs, {Levi S} and Judson, {Patricia L.} and Argenta, {Peter A} and Ghebre, {Rahel G} and Geller, {Melissa A} and Bliss, {Robin L.} and Boente, {Matthew P.} and Nahhas, {William A.} and Abu-Ghazaleh, {Samir Z.} and Chen, {M. Dwight} and Carson, {Linda F}",
year = "2008",
month = "1",
day = "15",
doi = "10.1002/cncr.23164",
language = "English (US)",
volume = "112",
pages = "331--339",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma

AU - Downs, Levi S

AU - Judson, Patricia L.

AU - Argenta, Peter A

AU - Ghebre, Rahel G

AU - Geller, Melissa A

AU - Bliss, Robin L.

AU - Boente, Matthew P.

AU - Nahhas, William A.

AU - Abu-Ghazaleh, Samir Z.

AU - Chen, M. Dwight

AU - Carson, Linda F

PY - 2008/1/15

Y1 - 2008/1/15

N2 - BACKGROUND. Thalidomide is an antiangiogenic agent with immune modulating potential. The objective of this study was to determine response rates among women who were treated for recurrent ovarian cancer using topotecan with or without thalidomide. METHODS. Women were enrolled in this multicenter, prospective, randomized phase 2 trial between April 2001 and July 2005. Eligible patients had recurrent epithelial ovarian carcinoma with measurable disease or elevated CA 125 values. Patients had received prior platinum-based chemotherapy. Treatment arms received topotecan at a dose of 1.25 mg/m2 on Days 1 through 5 of a 21-day cycle with or without thalidomide starting at a dose of 200 mg per day and then increasing the dose as tolerated. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria. The chi-square test was used to assess differences in response and toxicity, and the log-rank test was used to compare Kaplan-Meier survival curves. RESULTS. The analysis included 69 women (39 women in the control arm and 30 women in the thalidomide arm). Known prognostic factors, including platinum sensitivity, were represented equally in each arm. The median thalidomide dose was 200 mg per day. The overall response rate in the control arm was 21% (complete response [CR] rate, 18%; partial response [PR] rate, 3%) compared with 47% in the thalidomide arm (CR rate, 30%; PR rate, 17%) (P = .03). The median progression-free survival for the control arm was 4 months compared with 6 months in the thalidomide arm (P = .02). The median overall survival was 15 months in the control arm and 19 months in the thalidomide arm (P = .67). Toxicities were similar between groups. CONCLUSIONS. The addition of thalidomide to topotecan for the treatment of recurrent ovarian cancer appears to improve response rates, and the authors believe that it warrants study through larger phase 3 trials.

AB - BACKGROUND. Thalidomide is an antiangiogenic agent with immune modulating potential. The objective of this study was to determine response rates among women who were treated for recurrent ovarian cancer using topotecan with or without thalidomide. METHODS. Women were enrolled in this multicenter, prospective, randomized phase 2 trial between April 2001 and July 2005. Eligible patients had recurrent epithelial ovarian carcinoma with measurable disease or elevated CA 125 values. Patients had received prior platinum-based chemotherapy. Treatment arms received topotecan at a dose of 1.25 mg/m2 on Days 1 through 5 of a 21-day cycle with or without thalidomide starting at a dose of 200 mg per day and then increasing the dose as tolerated. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria. The chi-square test was used to assess differences in response and toxicity, and the log-rank test was used to compare Kaplan-Meier survival curves. RESULTS. The analysis included 69 women (39 women in the control arm and 30 women in the thalidomide arm). Known prognostic factors, including platinum sensitivity, were represented equally in each arm. The median thalidomide dose was 200 mg per day. The overall response rate in the control arm was 21% (complete response [CR] rate, 18%; partial response [PR] rate, 3%) compared with 47% in the thalidomide arm (CR rate, 30%; PR rate, 17%) (P = .03). The median progression-free survival for the control arm was 4 months compared with 6 months in the thalidomide arm (P = .02). The median overall survival was 15 months in the control arm and 19 months in the thalidomide arm (P = .67). Toxicities were similar between groups. CONCLUSIONS. The addition of thalidomide to topotecan for the treatment of recurrent ovarian cancer appears to improve response rates, and the authors believe that it warrants study through larger phase 3 trials.

KW - Angiogenesis inhibitor

KW - Phase 2 trial

KW - Platinum sensitivity

KW - Recurrent ovarian cancer

KW - System for Thalidomide Education and Prescribing Safety

UR - http://www.scopus.com/inward/record.url?scp=38049027230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049027230&partnerID=8YFLogxK

U2 - 10.1002/cncr.23164

DO - 10.1002/cncr.23164

M3 - Article

C2 - 18058810

AN - SCOPUS:38049027230

VL - 112

SP - 331

EP - 339

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -